Welcome back to the channel. By popular demand, today I'm going to walk through some thoughts,

some slides for vaccination under five. The ACHIP met this morning, the advisory committee of

immunologic practices for the U.S. CDC, and the Verback and FDA have been busy this week.

And so I have poured through the 200, 300 pages of documentation from the USFDA as they review the

Pfizer and the Moderna products.

I'm not going to talk about everything.

I'm going to focus on vaccination under five rather than on, you know, Moderna's bid to also

vaccinated adolescents.

And I think I'm going to view this through a policy lens. Every single one of my slides will come from the either Verback slides by the FDA,

by Moderna, or the packet of information that was distributed by the FDA. All right, with that

introduction, let's hit it, Vax Under 5.

This was a figure that I see was used in the introduction.

It was rates of monthly COVID-associated hospitalizations by vaccination status among

children and adolescents, five to 17 years old.

And what it shows you, the dotted lines are the troublesome. Those are the

adolescents, 12 to 17, who are unvaccinated and the children 5 to 11 were unvaccinated. And the

solid lines are the ones who have been vaccinated, at least with the primary series. And the

argument here is that these vaccines, even though the randomized control trials that led to

authorization weren't powered or suited to assess reductions in hospitalization, of course, they'd have to be mega trials, hundreds of thousands, perhaps even millions in each arm. You see here from observational data that there's a reduction. I want to put a bit of asterisk here. This is an observational data set. And of course, there are big problems with

observational data. One big problem, we have to admit, there is a difference between parents of

kids 5 to 11 who rushed out and were that one-third of parents who quickly got their kids vaccinated

and the 2-thirds of parents who didn't. They have differences not only

...